Phase II trial of a 75‐mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non‐small cell lung cancer Academic Article Article uri icon

Overview

MeSH Major

  • Adenoviridae
  • Genetic Vectors
  • Myocardial Ischemia
  • Vascular Endothelial Growth Factor A

abstract

  • Docetaxel administered at a dose of 75 mg/m2 every 21 days shows significant antitumor activity in untreated patients with NSCLC: Neutropenia is comparable with that observed at a 100-mg/m2 dose. The number of infusional reactions and rash decreased when docetaxel at this dose was administered with prednisone. Based on response rates observed in trials using a 100-mg/m2 dose with similar degrees of neutropenia, a 100-mg/m2 dose with steroid pretreatment is recommended future trials.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950215)75:4<968::AID-CNCR2820750411>3.0.CO;2-Y

PubMed ID

  • 7842417

Additional Document Info

start page

  • 968

end page

  • 72

volume

  • 75

number

  • 4